Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.40
Bid: 9.32
Ask: 9.48
Change: 0.00 (0.00%)
Spread: 0.16 (1.717%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.40
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

OBD to present at BioTech Pharma Summit

20 Feb 2020 07:00

RNS Number : 5335D
Oxford BioDynamics PLC
20 February 2020
 

20 February 2020

Oxford BioDynamics Plc

 

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Oxford BioDynamics to present at BioTech Pharma Summit: Liquid Biopsy 2020 in Lisbon, Portugal

 

·; Results from non-invasive blood-based EpiSwitch™ biomarker studies demonstrate the relevance of the 3D Genomics biomarker modality to clinical outcomes in patients, across multiple applications.

·; Blood-based stratifications of patients for diagnostic, predictive and prognostic applications in neurodegeneration, inflammation and immuno-oncology discussed and directly compared to current gold standards.

·; The rise of innovative technologies in molecular biomarkers offers the possibility of developing new gold standards for personalized medicine.

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that data yielded by the application of its 3D genome architecture technology platform, EpiSwitch™, will be presented at the BioTech Pharma Summit: Liquid Biopsy 2020 held in Lisbon, Portugal on February 20-21, 2020. The summit brings together leaders in the field from pharma, biotech, and diagnostic companies and healthcare providers, fostering collaboration between stakeholders in liquid biopsy, molecular pathology and precision medicine. The expanding field of circulating biomarkers of various classes is redefining the gold standards of personalised healthcare testing.

 

OBD's presentation "3D Genome Architecture as Biomarker Modality" sets out the advantages of its EpiSwitch™ biomarker platform, the relevance of its biomarkers to clinical outcomes and the systemic nature of its biomarker signatures, as detected non-invasively in peripheral blood.

 

The presentation will focus on examples of diagnostic, prognostic and predictive stratifications in patients, including in the following disease areas and indications:

- Neurodegeneration - prognostic biomarkers for ALS;

- Inflammation - predictive biomarkers for Rheumatoid Arthritis;

- Oncology - prognostic biomarkers for DLBCL;

- Oncology - predictive biomarkers for PD-1/PD-L1 immuno-checkpoint inhibitors.

 

Alexandre Akoulitchev, Director and Chief Scientific Officer of Oxford BioDynamics, commented, "We are building an impressive body of evidence for the direct relevance to clinical outcomes of the non-invasive blood-based biomarker readouts generated by our EpiSwitch™ platform. The quality of the classification results delivered - from rheumatoid arthritis and neurodegeneration to immuno-oncology - is a reflection of the fundamental biological nature of regulatory 3D genome architecture and the robustness of the automated, high resolution EpiSwitch™ technology used to monitor it. We are inspired by the full potential of our platform and its role in the future development of precision medicine. "

 

 

For further details please contact:

 

Oxford BioDynamics Plc

Christian Hoyer Millar, CEO

Alexandre Akoulitchev, CSO

Paul Stockdale, CFO

 

 

+44 (0)1865 518910

FTI Consulting

Financial Public Relations Adviser

Natalie Garland-Collins

 

+44 (0)20 3727 1000

 

About EpiSwitch™

 

EpiSwitch™ is a novel epigenetic-based technology platform that supports precision medicine initiatives including: prediction of response to therapy, patient prognosis, disease diagnosis & subtyping and residual disease monitoring. The result of robust, validated, award-winning technology and methodology, EpiSwitch™ stratifies patients based on their genomic architecture to reduce the risk, cost and time to market for therapeutic development programmes, provide significant insights into disease mechanisms and help personalize therapeutics to ensure better outcomes. To learn more about EpiSwitch™, please visit https://www.oxfordbiodynamics.com/technology/.

 

About Oxford BioDynamics Plc 

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical. 

 

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

 

The Company is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAKZGMZMLVGGZZ
Date   Source Headline
27th Mar 20242:18 pmRNSResult of AGM
14th Mar 20247:00 amRNSResults of Fundraising
13th Mar 20244:45 pmRNSPrimaryBid Offer
13th Mar 20244:40 pmRNSProposed Fundraising
22nd Feb 20242:30 pmRNSAnnual Report & Accounts
17th Jan 20247:00 amRNSPreliminary Results and Notice of AGM
21st Dec 20237:20 amRNSNotice of Results
13th Nov 202310:22 amRNSDirector/PDMR Shareholding
8th Nov 20237:00 amRNSOBD strengths commercial leadership
7th Nov 202312:30 pmRNSHolding(s) in Company
6th Nov 20235:04 pmRNSHolding(s) in Company
3rd Nov 20239:29 amRNSDirector/PDMR Shareholding
23rd Oct 202311:09 amRNSPDMR Dealing / Grant of Share Options
20th Oct 20239:45 amRNSDirector/PDMR Shareholding
18th Oct 20237:00 amRNSBupa UK to cover EpiSwitch® CiRT for customers
6th Oct 20235:44 pmRNSDirector/PDMR Shareholding
3rd Oct 20234:37 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSOBD receives reimbursement code for PSE test
26th Sep 20237:00 amRNSOBD launches 94% accurate PSE test in US and UK
7th Sep 202310:18 amRNSHolding(s) in Company
1st Sep 202312:34 pmRNSAmendment: Director/PDMR Shareholding
31st Aug 20234:02 pmRNSHolding(s) in Company
25th Aug 20239:00 amRNSHolding(s) in Company
22nd Aug 20233:58 pmRNSHolding(s) in Company
22nd Aug 20237:00 amRNSHolding(s) in Company
22nd Aug 20237:00 amRNSHolding(s) in Company
18th Aug 202311:44 amRNSResult of General Meeting
8th Aug 20234:00 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSResults of PrimaryBid Offer
2nd Aug 20237:00 amRNSResult of Placing and Subscription
1st Aug 20234:55 pmRNSPrimaryBid Offer
1st Aug 20234:54 pmRNSProposed Fundraising
30th May 20237:00 amRNSHalf-year Report
16th May 20237:00 amRNSNotice of Interim Results and Investor Webinar
15th May 20237:00 amRNSCiRT expanded validation for ICI immunotherapies
2nd May 20237:00 amRNSUS PACT Award for prognosis test for IOrelated HPD
18th Apr 20237:00 amRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSBusiness update for PSE and CiRT tests
30th Mar 20231:04 pmRNSResult of AGM
23rd Mar 20233:19 pmRNSHolding(s) in Company
22nd Mar 20232:22 pmRNSHolding(s) in Company
15th Mar 202311:43 amRNSAIM Rule 17 Schedule 2(g) Update
3rd Mar 20234:33 pmRNSPublication of FY22 Annual Report
23rd Feb 202310:36 amRNSPDMR Dealing
6th Feb 20237:00 amRNSOBD Prostate Screening EpiSwitch Blood Test Update
27th Jan 20232:36 pmRNSDirector/PDMR Shareholding
24th Jan 20237:00 amRNSPreliminary Results and Notice of AGM
21st Dec 20227:00 amRNSNotice of FY22 Results and Investor Webinar
19th Dec 20227:00 amRNSOBD in San Francisco for JPM Healthcare conf 2023
16th Dec 20227:00 amRNSInitial assessment of EpiSwitch assay in ALS trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.